

Supplementary Materials

Table S1. Characteristics of post-COVID-19 patients.

Patient	Group	Sex	Age	Hospitalization	Months from acute COVID-19	Arthralgia	Myalgia	Dyspnea	Asthenia	Paresthesia	Dizziness	Anxiety	Insomnia	Headache	Brain fog	Anosmia	Dysgeusia
Patient 1	NSP	Male	25	No	6	No	No	No	No	No	No	No	No	No	No	No	No
Patient 2	NSP	Female	26	No	8	No	No	No	No	No	No	No	No	No	No	No	No
Patient 3	NSP	Male	62	No	6	No	No	No	No	No	No	No	No	No	No	No	No
Patient 4	NSP	Female	56	Yes	13	No	No	No	No	No	No	No	No	No	No	No	No
Patient 5	NSP	Female	52	No	3	No	No	No	No	No	No	No	No	No	No	No	No
Patient 6	PSP	Female	61	No	13	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	No	No
Patient 6	TTP					Complete R.	Complete R.	Complete R.	Complete R.	Complete R.	No	Complete R.	Complete R.	Complete R.	No	No	No
Patient 7	PSP	Female	49	No	3	Yes	Yes	No	No	Yes	No	No	No	No	No	No	No
Patient 7	TTP					Partial R.	Partial R.	No	No	Complete R.	No	No	No	No	No	No	No
Patient 8	PSP	Male	56	Yes	13	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No
Patient 8	TTP					No R.	No R.	Partial R.	No R.	No R.	No R.	No R.	No R.	No	No R.	No R.	No
Patient 9	PSP	Female	43	No	8	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes
Patient 9	TTP					Partial R.	Partial R.	No R.	Partial R.	No R.	No R.	No	No R.	No R.	No R.	No R.	No R.
Patient 10	PSP	Female	44	No	12	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	No
Patient 10	TTP					Partial R.	Partial R.	No R.	No R.	No R.	No R.	No	No	No R.	No R.	No	No
Patient 11	PSP	Female	31	No	13	Yes	Yes	Yes	Yes	No	Yes	No	No	Yes	No	No	No
Patient 11	TTP					Complete R.	Partial R.	No R.	No R.	No	No R.	No	No	No R.	No	No	No
Patient 12	PSP	Female	30	No	7	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	No	No
Patient 12	TTP					Partial R.	Partial R.	No R.	Partial R.	No R.	No	No R.	No R.	No	No	No	No
Patient 13	PSP	Female	33	Yes	12	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No
Patient 13	TTP					No	No R.	No R.	Partial R.	No R.	Partial R.	No R.	Partial R.	Partial R.	No R.	No	No
Patient 14	PSP	Female	35	No	3	No	No	Yes	Yes	No	No	Yes	No	No	No	Yes	Yes

NSP: no symptoms patients; PSP: persistent symptoms patients; TTP: treated patients; R.: recovery.

Table S2. Hemogram of each individual.

Patients	NSP					PSP										TTP							Normal values
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P10	P11	P12	P13	P14	P6	P7	P8	P9	P10	P11	P12	P13	
Platelets	277	261	246	232	190	209	182	219	246	214	286	370	212	350	223	203	234	238	223	264	389	193	140 - 450
Neutrophils (10 ⁶ cells/uL)	3.2	2.6	3.7	4.3	3.2	3.3	4.5	4.1	2.3	2.6	2.2	5.6	3.2	4.8	6	11	5.2	6.3	5.6	7	10.2	7.6	1.8 - 7.6
Neutrophils (%)	52.4	49.3	61.5	59.8	59.1	49.5	66.2	62.1	56.5	49.8	37.8	62.1	52.2	56.5	83.9	92.9	82.7	85.9	83.7	85.3	88.2	78	41.0 - 72.7
Lymphocytes (10 ⁶ cells/uL)	2.3	2.2	1.8	2.1	1.8	2.8	1.7	1.7	1.4	2.1	2.7	2.3	2.3	3.1	1.1	0.7	0.9	0.9	1	1.1	1.1	1.6	1.2 - 4.2
Lymphocytes (%)	38.2	42.5	29.5	29.4	32.5	42	24.5	25.9	33.4	40.3	46.8	25.3	37.4	36.6	15.1	5.9	14.2	12.3	14.2	13.7	9.7	16.4	20.1 - 49.0
Monocytes (10 ⁶ cells/uL)	0.4	0.4	0.3	0.6	0.4	0.4	0.6	0.6	0.4	0.4	0.4	0.8	0.6	0.5	0.1	0.1	0.2	0.1	0.1	0.1	0.2	0.5	0.2 - 0.9
Monocytes (%)	6.9	6.9	5.3	7.9	6.8	6.6	8.1	8.5	8.9	7.5	6.9	8.6	10.3	6.1	0.9	1.1	2.6	1.6	1.8	0.8	1.9	5.5	3.4 - 10.6
Eosinophils (10 ⁶ cells/uL)	0.1	0	0.2	0.1	0.1	0.1	0.1	0.1	0	0.1	0.5	0.3	0	0	0	0	0	0	0	0	0	0	0.0 - 0.5
Eosinophils (%)	2.1	0.9	3.2	2.1	1	1.4	0.8	2.3	0.5	1.7	7.7	3.7	0	0.4	0	0	0.1	0	0.1	0	0	0	0.3 - 5.6

Basophils (10 ⁶ cells/uL)	0	0	0	0.1	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0 - 0.2
Basophils (%)	0.4	0.4	0.5	0.8	0.6	0.5	0.4	1.2	0.7	0.7	0.8	0.3	0.1	0.4	0.1	0.1	0.4	0.2	0.2	0.2	0.2	0.1	0.2 - 2.1

Table S3. Autoantibodies.

[illegible]

Neuronal															
GAD65	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
SOX1	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Ma2	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Ma1	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Amphiphysin	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
CV 2 (CRMP5)	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Ri	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Yo	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
HuD	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative

NSP: no symptoms patients; PSP: persistent symptoms patients; TTP: treated patients.